https://doi.org/ 10.33472/AFJBS.6.10.2024.700-712

RECENT ADVANCES IN METAL OXIDE NANOPARTICLES FOR CANCER THERAPY: A COMPREHENSIVE REVIEW

SHEFALI SONI[1]*, RAKHEE KAPADIA[2]

1. **Miss Shefali Soni** , Research Scholar, Sanjeev Agrawal Global Educational University Bhopal, M.P., India
2. **Dr. Rakhee Kapadia**, Associate Professor, Sanjeev Agrawal Global Educational University, Bhopal, M.P., India

*__Ms Shefali Soni,__ PhD Research Scholar, Sanjeev Agrawal Global Educational University, Bhopal, M.P., India

Email Id: shalusoni823@gmail.com

Article History
Volume 6,Issue 10, Feb 2024
Received:17 Apr 2024
Accepted : 05 May 2024

doi: 10.33472/AFJBS.6.10.2024.700-712

ABSTRACT:

Cancer remains a formidable global health challenge, necessitating innovative therapeutic strategies. In recent years, metal oxide nanoparticles (MONPs) have emerged as promising candidates for cancer therapy due to their unique physicochemical properties and biocompatibility. This abstract provides a concise overview of the current approaches and developments in utilizing MONPs for cancer treatment. There are many synthesis methods employed to engineer MONPs with tailored size, shape, and surface properties. Various metal oxides, such as iron oxide (Fe3O4), zinc oxide (ZnO), titanium dioxide (TiO2), and others, are discussed in the context of their fabrication and modification for optimal therapeutic outcomes. In diagnosis and imaging, MONPs plays important role. With their inherent magnetic, optical, and photo acoustic properties, MONPs serve as contrast agents for various imaging modalities, enabling early detection and precise monitoring of tumour progression. In current scenario, lot of therapeutic mechanisms of MONPs, emphasizing their potential as drug delivery vehicles, photo thermal agents, and radio sensitizers are present. The ability of MONPs to encapsulate and deliver chemotherapeutic agents selectively to cancer cells enhances treatment efficacy while minimizing off-target effects. Additionally, their photo thermal and radio sensitizing properties enable synergistic combination therapies for improved outcomes. Finally, the abstract concludes with a forward-looking perspective on the challenges and future directions in the field of metal oxide nanoparticles for cancer therapy. Ongoing efforts to optimize MONPs for clinical translation, overcome hurdles related to scalability, and enhance our understanding of their in vivo behaviour are highlighted.

In summary, this abstract provides a comprehensive snapshot of the current state of research on metal oxide nanoparticles for cancer therapy, underscoring their potential as versatile and effective tools in the fight against cancer.

KEYWORDS: Nanotechnology, Metal oxide nanoparticles, cancer therapy

INTRODUCTION: Cancer remains a significant global health concern, and novel strategies for enhancing the efficacy of anticancer drugs are continually sought[1].At its core, cancer is a disease of our own making, born from the intricate genetic fabric of our bodies, where the most intricate and delicate regulatory mechanisms can falter. Within the DNA of our cells, mistakes, mutations, and triggers collide, and the result can be a cell that breaks free from the orderly constraints of its peers. Unburdened by the controls that typically manage growth and division, this renegade cell embarks on an unchecked journey[2]. It multiplies, forming a tumor, invading nearby tissues, and, in more advanced cases, launching an assault on distant parts of the body.

The impact of cancer goes beyond biology. It touches the realms of human emotion, economics, and society as a whole. Cancer diagnoses carry with them fear and uncertainty, not only for the individuals who must confront the disease but also for their loved ones. The financial and emotional burdens of cancer treatment are substantial, and the disease can disrupt daily life, work, and relationships[3].

Nevertheless, the story of cancer is not one of despair alone. It is a tale of resilience and determination, a story of ceaseless efforts by scientists, clinicians, and advocates. Over the years, a deeper understanding of the disease has emerged, leading to remarkable advances in diagnosis, treatment, and prevention. Early detection, innovative therapies, and lifestyle changes are offering hope and extending the lives of many cancer patients[4].

Difference between cancer cells and normal cells[5]:

1. **Uncontrolled Growth:**
    - Cancer cells: Cancer cells exhibit uncontrolled and rapid growth. They divide and multiply without responding to the body's natural mechanisms that regulate cell growth.
    - Normal Cells: Normal cells have a controlled and regulated growth pattern. They grow, divide, and die in an orderly and controlled manner, following the body's requirements.

2. **Programmed Cell Death (Apoptosis):**
    - Cancer Cells: Cancer cells often evade apoptosis, the natural process of programmed cell death that eliminates abnormal or damaged cells. As a result, they can accumulate in the body.
    - Normal Cells: Normal cells respond to signals that trigger apoptosis when they become old, damaged, or dysfunctional. This process helps maintain tissue health and eliminate cells that may become cancerous.

3. **Tumor Formation:**
    - Cancer Cells: Cancer cells have the ability to form tumors. These tumors can be benign or malignant, but they usually result from the uncontrolled division and growth of cancer cells[6].

- Normal Cells: Normal cells generally do not form tumors. In cases where benign tumors occur, they are composed of normal cells that have overgrown but do not invade surrounding tissues.

4. **Invasion and Metastasis:**
   - Cancer Cells: One of the most distinguishing features of cancer is its ability to invade nearby tissues and metastasize to distant parts of the body. Cancer cells can break away from the primary tumor, enter the bloodstream or lymphatic system, and establish secondary tumors in other organs[7].
   - Normal Cells: Normal cells typically stay within their designated tissues and do not invade neighbouring tissues or metastasize to other parts of the body.
5. **Shape and Structure:**
   - Cancer Cells: Cancer cells often exhibit irregular shapes and abnormal structures. These structural changes can be observed under a microscope and are one way pathologists identify cancer.
   - Normal Cells: Normal cells maintain their typical shape and structure, adhering to the defined organization of tissues and organs.
6. **Genetic Mutations:**
   - Cancer Cells: Genetic mutations are a hallmark of cancer. These mutations disrupt the DNA within cancer cells, causing them to behave abnormally. Mutations can affect genes that regulate cell growth, DNA repair, and other essential functions.
   - Normal Cells: While normal cells may accumulate some mutations over time, they typically retain the ability to repair and regulate their DNA to maintain normal cellular function[8].
7. **Response to Signals:**
   - Cancer Cells: Cancer cells often fail to respond to signals from the immune system that would normally lead to their destruction. This helps them evade the body's natural defence mechanisms.
   - Normal Cells: Normal cells respond to signals from the immune system and can be eliminated if they become cancerous or damaged[9].



Figure1. Normal cells Vs Cancerous cells.

Metal Oxide nanoparticles:

In the realm of nanotechnology, the manipulation of materials at the nanoscale has sparked a scientific revolution, offering unprecedented opportunities for innovation and advancement across multiple disciplines. Among the myriad of nano materials, metal oxide nanoparticles (MONPs) have emerged as captivating entities, commanding attention due to their unique physicochemical properties and versatile applications. At the heart of their appeal lies the distinctive behaviour that arises when metals intertwine with oxygen on a nanoscale. The reduction in size to the nanometre range bestows MONPs with novel characteristics, differing significantly from their bulk counterparts. This transformation not only unlocks inherent properties but also introduces a plethora of possibilities for tailored applications in fields as diverse as medicine, electronics, catalysis, and environmental science[10].

The synthesis of MONPs has become an art form, with researchers employing sophisticated techniques to precisely engineer their size, shape, and surface properties. This precision opens avenues for customizing MONPs to meet specific requirements, enhancing their performance in targeted applications. From iron oxide to zinc oxide, and titanium dioxide to copper oxide, the palette of metal oxides explored at the nanoscale is expansive, each offering a unique set of properties that researchers are harnessing for diverse purposes[11].

In this context, biomedical applications have witnessed a particularly profound impact. MONPs exhibit unparalleled potential in targeted drug delivery, imaging, and therapeutic interventions, especially in the burgeoning field of cancer therapy. Their ability to navigate biological barriers, coupled with the possibility of functionalization for targeted delivery, marks them as promising contenders in the quest for more effective and less invasive treatment strategies[12].

Beyond medicine, MONPs find their way into catalytic processes, enhancing efficiency in chemical transformations and environmental remediation. Their role in electronics, energy storage, and various other domains further underscores their significance in shaping the technological landscape. However, as with any revolutionary advancement, challenges accompany the promise. Concerns over toxicity, stability, and scalability require meticulous exploration and resolution to ensure the safe and sustainable integration of MONPs into practical applications.

Figure 2. Different applications of metal oxide nanoparticles.

MONPs in cancer therapy[13]:

Cancer, a complex and multifaceted disease, demands innovative approaches for diagnosis and treatment. Metal oxide nanoparticles (MONPs) have emerged as promising candidates in the realm of cancer research, showcasing unique properties that make them versatile tools in various aspects of cancer management. This comprehensive overview explores the diverse applications of MONPs in cancer, encompassing diagnostics, imaging, therapy, and the associated challenges.

1. Diagnostic Applications:

a. Biosensors:

MONPs, particularly those with semiconductor properties like zinc oxide (ZnO) or titanium dioxide (TiO2), play a pivotal role in biosensor development.

Their high surface area allows for efficient immobilization of bio molecules, facilitating sensitive and selective detection of cancer-related markers.

b. Early Detection:

MONPs, such as iron oxide nanoparticles (IONPs), are employed as contrast agents in imaging techniques like magnetic resonance imaging (MRI) for early cancer detection.

Early diagnosis is crucial for initiating timely interventions and improving patient outcomes.

2. Imaging Modalities:

a. Magnetic Resonance Imaging (MRI):

IONPs with magnetic properties enhance contrast in MRI, providing detailed anatomical information for precise tumor localization.

Functionalized IONPs enable targeted imaging and improved diagnostic accuracy.

b. Multimodal Imaging:

The multifunctionality of MONPs allows for their use in multimodal imaging, combining different imaging techniques to provide comprehensive information for cancer diagnosis and monitoring.



Figure 3. Different types of nanoparticles being used in the diagnosis and therapy of several human diseases, including cancer.

3. Therapeutic Applications:

a. Drug Delivery: MONPs are utilized as drug carriers, allowing for targeted drug delivery to cancer cells .Surface modifications enable controlled release, minimizing systemic side effects and improving therapeutic efficacy.

b. Photothermal Therapy (PTT): Certain MONPs, like gold and TiO2 nanoparticles, exhibit photothermal properties.PTT involves irradiating the nanoparticles with light, leading to localized heating and selective ablation of cancer cells.

c. Radiotherapy Enhancement: Some MONPs act as radiosensitizers, enhancing the sensitivity of cancer cells to radiation therapy. This synergistic approach improves the therapeutic outcome while potentially reducing radiation doses.

d. Reactive Oxygen Species (ROS) Generation: Certain MONPs can generate reactive oxygen species (ROS) under specific conditions, inducing oxidative stress and promoting apoptosis in cancer cells.



Figure 4. Biological Applications of Metal oxide Nanoparticles

4. Challenges and Considerations:

a. Toxicity: Understanding the potential toxicity of MONPs is crucial for safe application in cancer therapy Surface modifications and biocompatible coatings are explored to mitigate potential adverse effects.

b. Bio distribution and Clearance Investigating the in vivo behaviour of MONPs, including their bio distribution and clearance, is essential for ensuring their safe clinical translation.

5. Future Directions:

a. Combination Therapies: Ongoing research focuses on the synergistic effects of MONPs in combination with traditional cancer therapies, enhancing overall treatment outcomes.

b. Clinical Translation: Bridging the gap between preclinical studies and clinical applications is a key challenge, requiring robust and reproducible findings. In conclusion, metal oxide nanoparticles represent a dynamic and promising avenue in cancer research, offering a multifaceted approach to diagnosis and treatment. As our understanding of their properties and behaviour advances, the potential for MONPs to revolutionize cancer management continues to grow, positioning them as valuable assets in the ongoing quest for effective and targeted cancer solutions

METHOD OF PREPARATION OF METAL OXIDE NANOPARTICLES[14]:

The synthesis of metal oxide nanoparticles (MONPs) for cancer treatment involves various methods that allow for precise control over particle size, shape, and surface properties. The choice of method depends on the specific requirements for therapeutic applications. Here, we delve into some commonly employed methods, each offering unique advantages in the context of cancer treatment:

1. Chemical Precipitation:

Principle: Metal salts are dissolved in a solvent, and a precipitating agent is added, leading to the formation of metal oxide nanoparticles.

Procedure: Metal ions are mixed in a solution, and a precipitating agent (e.g., hydroxide ions) is added drop wise. The resulting precipitate is then washed, dried and calcined to obtain metal oxide nanoparticles.

2. Sol-Gel Synthesis:

Principle: Involves the hydrolysis and condensation of metal oxides to form a sol, which undergoes gelation and subsequent drying to produce metal oxide nanoparticles.

Procedure: Metal oxides are hydrolyzed to form a sol. The sol undergoes gelation, and the resulting gel is dried and calcined to obtain metal oxide nanoparticles.

3. Co-precipitation:

Principle: Simultaneous precipitation of multiple metal ions to form mixed metal oxide nanoparticles.

Procedure: Metal salts containing different metal ions are dissolved together, and a precipitating agent is added to induce co-precipitation. The resulting mixture is processed to obtain mixed metal oxide nanoparticles.

4. Hydrothermal Synthesis:

Principle: Reaction of metal precursors in an aqueous solution under high-temperature and high-pressure conditions.

Procedure: Metal precursors are dissolved in water, and the solution is sealed in a high-pressure vessel and heated at elevated temperatures. The resulting nanoparticles are obtained after cooling and processing.

5. Microemulsion Method:

Principle: Utilizes microemulsions, stable mixtures of water, oil, and surfactant, as reaction media for nanoparticles synthesis.

Procedure: Metal precursors are introduced into the microemulsion system, where they undergo reactions leading to the formation of metal oxide nanoparticles. The surfactant stabilizes the nanoparticles.

6. Green Synthesis:

Principle: Involves the use of natural extracts or biomolecules as reducing and stabilizing agents for nanoparticles synthesis.

Procedure: Metal precursors are mixed with a plant extract or biomolecule, initiating the reduction process. The resulting nanoparticles are typically biocompatible and suitable for medical applications.

7. Template-Assisted Synthesis:

Principle: Uses a template structure to control the size and morphology of metal oxide nanoparticles.

Procedure: The metal precursor is introduced into a template, and the subsequent reaction results in the formation of nanoparticles with shapes and sizes dictated by the template.

These methods offer versatility in tailoring MONPs for specific applications in cancer treatment. It's crucial to consider factors such as biocompatibility, scalability, and the intended use (e.g., drug delivery, imaging, or therapy) during the selection of a synthesis method. Furthermore, rigorous characterization and testing for toxicity and efficacy are imperative before the clinical translation of metal oxide nanoparticles in cancer treatment

Mechanism action of MONPs[15]:



Figure 5 : Mechanism of action of MONPs

Metal oxide nanoparticles have gained significant attention in the field of cancer treatment due to their unique properties that can be exploited for therapeutic purposes. One such metal oxide nanoparticles is titanium dioxide (TiO2). The mechanism of action of metal oxide nanoparticles in cancer treatment involves several aspects:

Photodynamic Therapy (PDT):

Metal oxide nanoparticles, such as TiO2, can be used in photodynamic therapy. These nanoparticles can generate reactive oxygen species (ROS) under light irradiation, especially in the presence of oxygen. The ROS, such as singlet oxygen, can induce oxidative stress in cancer cells, leading to cell damage and apoptosis.

Hyperthermia Therapy:

Metal oxide nanoparticles can be engineered to absorb and convert light or electromagnetic radiation into heat. When these nanoparticles accumulate in the tumour tissue, they can be exposed to external stimuli (such as laser irradiation), leading to localized heating. The generated heat induces hyperthermia, causing thermal damage to cancer cells while sparing normal tissues.

Drug Delivery:

Metal oxide nanoparticles can serve as drug carriers for targeted drug delivery Surface modifications can be employed to enhance the nanoparticles' biocompatibility and allow for the attachment of therapeutic agents. These nanoparticles can selectively accumulate in the tumour tissue, releasing the loaded drugs in a controlled manner.

Enhanced Permeability and Retention (EPR) Effect:

Metal oxide nanoparticles can take advantage of the EPR effect, which is the tendency of nanoparticles to accumulate in tumour tissues due to their leaky vasculature. This passive targeting allows for the preferential accumulation of nanoparticles in the tumour, improving therapeutic efficacy.

Apoptosis Induction:

Metal oxide nanoparticles can trigger apoptosis (programmed cell death) in cancer cells. The nanoparticles may interfere with cell signalling pathways, leading to the activation of apoptotic pathways and subsequent cell death.

Imaging and Diagnostics:

Metal oxide nanoparticles can be utilized for imaging purposes, helping in the diagnosis and monitoring of cancer. Functionalization of nanoparticles with imaging agents allows for the visualization of tumors through various imaging techniques. It's important to note that the specific mechanism of action can vary depending on the type of metal oxide nanoparticles, its surface modifications, and the targeted cancer cells. Additionally, ongoing research aims to improve the effectiveness and safety of metal oxide nanoparticles for cancer treatment[16].

CONCLUSION AND FUTURE PERSPECTIVES:

In conclusion, metal oxide nanoparticles hold great promise in the realm of cancer treatment, showcasing a multifaceted approach to combat this complex disease. Their unique properties, including the ability to induce photodynamic therapy, generate hyperthermia, and act as drug carriers, contribute to their versatility in targeting and eradicating cancer cells. The

exploitation of the enhanced permeability and retention (EPR) effect, along with their potential for apoptosis induction, further underscores their significance in cancer therapy.

The field has witnessed encouraging advancements, demonstrating the feasibility of using metal oxide nanoparticles for targeted drug delivery, imaging, and therapeutic interventions. Moreover, ongoing research continues to refine the design, surface modification, and biocompatibility of these nanoparticles, aiming to enhance their efficacy while minimizing potential side effects. Despite these promising developments, challenges remain, including concerns about the long-term safety, biodegradability, and potential off-target effects of metal oxide nanoparticles. Addressing these issues will be crucial for the translation of these innovative strategies from preclinical studies to clinical applications.

In the future, the evolution of metal oxide nanoparticles in cancer treatment is likely to be influenced by interdisciplinary collaborations between materials scientists, biologists, clinicians, and engineers. This collaboration will drive the development of personalized and targeted therapies, paving the way for more effective and less invasive cancer treatments. As our understanding of the intricate interactions between nanoparticles and biological systems deepens, the potential for tailored and patient-specific interventions will become increasingly feasible.

In essence, the journey of metal oxide nanoparticles in cancer treatment holds promise not only for improving therapeutic outcomes but also for revolutionizing the paradigm of cancer care, ushering in an era of precision medicine where tailored treatments are designed to target the unique characteristics of individual tumours.

Metal oxide nanoparticles have emerged as promising agents in cancer treatment, offering a multifaceted approach to combat the complexities of the disease. These nanoparticles exhibit unique properties that enable diverse therapeutic strategies, including photodynamic therapy, hyperthermia induction, and targeted drug delivery. Their ability to exploit the enhanced permeability and retention effect facilitates selective accumulation in tumour tissues, enhancing treatment specificity. Ongoing research focuses on refining nanoparticles design for optimal biocompatibility and safety, exploring combination therapies, and harnessing immunomodulatory effects. With the potential for personalized treatments and real-time monitoring, metal oxide nanoparticles represent a transformative force in the future of cancer therapy, offering hope for more effective and targeted interventions with reduced side effects.

References:

1. Sengul, A.B. and Asmatulu, E., 2020. Toxicity of metal and metal oxide nanoparticles: a review. *Environmental Chemistry Letters*, *18*, pp.1659-1683.
2. Vinardell, M.P. and Mitjans, M., 2018. Metal/metal oxide nanoparticles for cancer therapy. *Nan oncology: Engineering nanomaterials for cancer therapy and diagnosis*, pp.341-364.
3. Vinardell, M.P. and Mitjans, M., 2015. Antitumor activities of metal oxide nanoparticles. *Nanomaterials*, *5*(2), pp.1004-1021.
4. Alphandéry, E., 2020. Bio-synthesized iron oxide nanoparticles for cancer treatment. *International journal of pharmaceutics*, *586*, p.119472.
5. Kievit, F.M. and Zhang, M., 2011. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. *Accounts of chemical research*, *44*(10), pp.853-862.

6. Laurent, S. and Mahmoudi, M., 2011. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. *International journal of molecular epidemiology and genetics*, *2*(4), p.367.
7. Zhao, Y., Zhao, X., Cheng, Y., Guo, X. and Yuan, W., 2018. Iron oxide nanoparticles-based vaccine delivery for cancer treatment. *Molecular pharmaceutics*, *15*(5), pp.1791-1799.
8. Martinkova, P., Brtnicky, M., Kynicky, J. and Pohanka, M., 2018. Iron oxide nanoparticles: innovative tool in cancer diagnosis and therapy. *Advanced healthcare materials*, *7*(5), p.1700932.
9. Murthy, S., Effiong, P. and Fei, C.C., 2020. Metal oxide nanoparticles in biomedical applications. In *Metal oxide powder technologies* (pp. 233-251). Elsevier.
10. Sharma, H., Kumar, K., Choudhary, C., Mishra, P.K. and Vaidya, B., 2016. Development and characterization of metal oxide nanoparticles for the delivery of anticancer drug. *Artificial cells, nanomedicine, and biotechnology*, *44*(2), pp.672-679.
11. Alphandéry, E., 2020. Iron oxide nanoparticles for therapeutic applications. *Drug discovery today*, *25*(1), pp.141-149.
12. Nabavinia, M. and Beltran-Huarac, J., 2020. Recent progress in iron oxide nanoparticles as therapeutic magnetic agents for cancer treatment and tissue engineering. *ACS Applied Bio Materials*, *3*(12), pp.8172-8187.
13. Malekigorji, M., Curtis, A.D. and Hoskins, C., 2014. The use of iron oxide nanoparticles for pancreatic cancer therapy. *Journal of Nanomedicine Research*, *1*(1).
14. Poller, J.M., Zaloga, J., Schreiber, E., Unterweger, H., Janko, C., Radon, P., Eberbeck, D., Trahms, L., Alexiou, C. and Friedrich, R.P., 2017. Selection of potential iron oxide nanoparticles for breast cancer treatment based on in vitro cytotoxicity and cellular uptake. *International journal of nanomedicine*, pp.3207-3220.
15. Saeed, M., Ren, W. and Wu, A., 2018. Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances. *Biomaterials science*, *6*(4), pp.708-725.
16. Yazdi, M.H., Sepehrizadeh, Z., Mahdavi, M., Shahverdi, A.R. and Faramarzi, M.A., 2016. Metal, Metalloid, and Oxide Nanoparticles for Therapeutic and Diagnostic Oncology. *Nano Biomedicine & Engineering*, *8*(4).
17. Dukhinova, M.S., Prilepskii, A.Y., Shtil, A.A. and Vinogradov, V.V., 2019. Metal oxide nanoparticles in therapeutic regulation of macrophage functions. *Nanomaterials*, *9*(11), p.1631.
18. Girigoswami, K., 2018. Toxicity of metal oxide nanoparticles. *Cellular and molecular toxicology of nanoparticles*, pp.99-122.
19. Dilnawaz, F., Singh, A., Mohanty, C. and Sahoo, S.K., 2010. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. *Biomaterials*, *31*(13), pp.3694-3706.
20. Israel, L.L., Galstyan, A., Holler, E. and Ljubimova, J.Y., 2020. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. *Journal of Controlled Release*, *320*, pp.45-62.

21. Quan, Q., Xie, J., Gao, H., Yang, M., Zhang, F., Liu, G., Lin, X., Wang, A., Eden, H.S., Lee, S. and Zhang, G., 2011. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. *Molecular pharmaceutics*, *8*(5), pp.1669-1676.
22. Peng, X.H., Qian, X., Mao, H., Wang, A.Y., Chen, Z., Nie, S. and Shin, D.M., 2008. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. *International journal of nanomedicine*, *3*(3), pp.311-321.
23. Santra, S., Kaittanis, C., Grimm, J. and Perez, J.M., 2009. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. *small*, *5*(16), pp.1862-1868.
24. Khan, M.I., Mohammad, A., Patil, G., Naqvi, S.A.H., Chauhan, L.K.S. and Ahmad, I., 2012. Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. *Biomaterials*, *33*(5), pp.1477-1488.
25. Pandey, N., Dhiman, S., Srivastava, T. and Majumder, S., 2016. Transition metal oxide nanoparticles are effective in inhibiting lung cancer cell survival in the hypoxic tumor microenvironment. *Chemico-biological interactions*, *254*, pp.221-230.
26. Andra, S., Balu, S.K., Jeevanandham, J., Muthalagu, M., Vidyavathy, M., Chan, Y.S. and Danquah, M.K., 2019. Phytosynthesized metal oxide nanoparticles for pharmaceutical applications. *Naunyn-Schmiedeberg's archives of pharmacology*, *392*, pp.755-771.
27. Caizer, C., 2017. Magnetic hyperthermia-using magnetic metal/oxide nanoparticles with potential in cancer therapy. *Metal Nanoparticles in Pharma*, pp.193-218.
28. Kandasamy, G. and Maity, D., 2015. Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics. *International journal of pharmaceutics*, *496*(2), pp.191-218.
29. Kossatz, S., Grandke, J., Couleaud, P., Latorre, A., Aires, A., Crosbie-Staunton, K., Ludwig, R., Dähring, H., Ettelt, V., Lazaro-Carrillo, A. and Calero, M., 2015. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. *Breast Cancer Research*, *17*, pp.1-17.
30. Xu, J.J., Zhang, W.C., Guo, Y.W., Chen, X.Y. and Zhang, Y.N., 2022. Metal nanoparticles as a promising technology in targeted cancer treatment. *Drug Delivery*, *29*(1), pp.664-678.
31. Vangijzegem, T., Lecomte, V., Ternad, I., Van Leuven, L., Muller, R.N., Stanicki, D. and Laurent, S., 2023. Superparamagnetic iron oxide nanoparticles (SPION): from fundamentals to state-of-the-art innovative applications for cancer therapy. *Pharmaceutics*, *15*(1), p.236.
32. Dadfar, S.M., Roemhild, K., Drude, N.I., von Stillfried, S., Knüchel, R., Kiessling, F. and Lammers, T., 2019. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. *Advanced drug delivery reviews*, *138*, pp.302-325.
33. Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J.S., Nejadnik, H., Goodman, S., Moseley, M. and Coussens, L.M., 2016. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. *Nature nanotechnology*, *11*(11), pp.986-994.

34. Hauser, A.K., Mitov, M.I., Daley, E.F., McGarry, R.C., Anderson, K.W. and Hilt, J.Z., 2016. Targeted iron oxide nanoparticles for the enhancement of radiation therapy. *Biomaterials*, *105*, pp.127-135.

35. Jain, T.K., Morales, M.A., Sahoo, S.K., Leslie-Pelecky, D.L. and Labhasetwar, V., 2005. Iron oxide nanoparticles for sustained delivery of anticancer agents. *Molecular pharmaceutics*, *2*(3), pp.194-205.